entertainment -WSS

entertainment

author：leisure time 2025-09-27 12:58:49 - browse：61397

Adam's take main illustration — Molly Ferguson/STAT

The Food and Drug Administration should halt Cassava Sciences’ ongoing clinical trials in Alzheimer’s disease. That, and other thoughts on the fallout from the City University of New York investigation that raised serious doubts about the science underpinning the company’s experimental drug simufilam.

Patient safety is paramount to the FDA, so stopping Cassava’s two Phase 3 studies is the ethically correct thing to do.The FDA has the power to place clinical holds on experimental drugs when there’s evidence of an unacceptable safety risk to study participants. Simufilam doesn’t appear to be toxic. It’s not causing dangerous side effects. But study participants can also be harmed when they volunteer for a clinical trial based on false or misleading information about a drug’s potential efficacy.

The CUNY committee charged with investigating Cassava’s principal scientific collaborator, the neuroscientist Hoau-Yan Wang, could not definitively prove that Wang faked simufilam data, but that’s only because he refused to turn over original data and primary research records that the committee had requested to examine. Wang also claimed that boxes of research records relevant to the investigation were thrown away. The investigative report was first made public last week in the journal Science.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Novo pauses ads for weight loss drug Wegovy amid demand

hotspot

WSS

Mom launches Girl Scout troop for LGBTQ youth in Texas

Cybersecurity threat forces Lurie Children's to take systems offline

Biogen nominates mother of director’s child to replace him on board

Vertigo drug brings hope for rare neuron disorder, Niemann

Vertex non

Biden administration opens offers in Medicare drug price negotiations

hotspot

entertainment

leisure time

Hollywood unions extend contract negotiations for actors

Biden administration opens offers in Medicare drug price negotiations

In age of alternative facts, a scholarly course on calling out crap

ARCH Venture Partners is raising $3 billion for a life sciences fund

In age of alternative facts, a scholarly course on calling out crap

The lessons of Aduhelm, an Alzheimer's drug that was not to be

Peter Hotez and the public health issue of online harassment

Tennessee law changes starting July 1 will restrict trans health care and fund more school safety

Medicare details structure of new drug price negotiation program

We're not in Australia anymore: Kansas cops jump into action to save kangaroo

explore

FDA drug safety: Singulair case shows systemic surveillance flaws

Reanimated hearts work just as well for transplants, study finds

The real point of Kenneth Smith’s execution by nitrogen gas

Vertigo drug brings hope for rare neuron disorder, Niemann

Medicare drug price negotiation’s day in court

Covid misinformation case heads to Supreme Court

hotspot

focus

leisure time

Wikipedia